article thumbnail

Treatment shows strong potential for ALK-driven neuroblastoma

European Pharmaceutical Review

In the Phase I New Approaches to Neuroblastoma Therapy (NANT) trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in patients with relapsed/refractory anaplastic lymphoma kinase (ALK)-driven neuroblastoma. In 2008, the ALK gene was found to hold a key role in the disease.

article thumbnail

Targeting ovarian cancer with a novel antibody therapeutic

European Pharmaceutical Review

This authorisation of the antibody drug conjugate Elahere provides a much needed clinically meaningful option for women living with this type of ovarian cancer, whose disease returns because they develop resistance to platinum-based chemotherapy regimens. 2008; 28(6A):35673572. Int J Gynecol Cancer. 2022; 32(6). Anticancer Res.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

Chemotherapy still accounted for 72.6% Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% While all of the top ten best-selling oncology drugs in the US in 2019 were innovative therapies, four out of the top ten best-selling oncology drugs in China were for conventional chemotherapy. “In

article thumbnail

Takeda farms out cancer drug alisertib to Puma Biotech

pharmaphorum

billion buyout of Millennium Pharma way back in 2008 – but those were dashed in 2015 when the drug failed to move the needle in a trial involving patients with peripheral T-cell lymphoma (PTCL). Takeda is also in line for just over $287 million in potential milestone payments, plus royalties on net sales if it reaches the market.

article thumbnail

Laurent Bonnac, PhD

Blog: Ask a Student Pharmacist

Antimicrobial agents and chemotherapy. Antimicrobial agents and chemotherapy. Antiviral chemistry & chemotherapy. 2008; 15(7):650-70. Rawson JM, Daly MB, Xie J, Clouser CL, Landman SR, Reilly CS, Bonnac Laurent , Kim B, Patterson SE, Mansky LM. 2016; 60(4):2318-25. Dual anti-HIV mechanism of clofarabine. Retrovirology.

article thumbnail

Jiashu Xie, PhD

Blog: Ask a Student Pharmacist

2008; 28(8): 1386-1389. Publications He T, Edwards TC, Majima R, Jung E, Kankanala J, Xie J , Geraghty RJ, Wang Z. Matrix effects in bioanalysis by LC/MS. Chin J Pharm Anal. Xie J , Ding C, Ge Q, Zhou Z, Zhi X. J Chromatogr B Analyt Technol Biomed Life Sci.

article thumbnail

Diverse Voices in Quality: Michelle Juhanson

PQA

I attended a CMS Star Ratings Conference in 2008, and I met Jonathan Blum, who worked at CMS. I finished chemotherapy in January 2020, had surgery in March 2020, and finished radiation in June 2020. Tell us about your background and how you became involved in medication use quality. I just liked doing a good job.